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Abstract
Background: The defects in DNA repair genes are potentially linked to development and response to therapy in
medulloblastoma. Therefore the purpose of this study was to establish the spectrum and frequency of germline
variants in selected DNA repair genes and their impact on response to chemotherapy in medulloblastoma patients.
Methods: The following genes were investigated in 102 paediatric patients: MSH2 and RAD50 using targeted gene
panel sequencing and NBN variants (p.I171V and p.K219fs*19) by Sanger sequencing. In three patients with
presence of rare life-threatening adverse events (AE) and no detected variants in the analyzed genes, whole exome
sequencing was performed. Based on combination of molecular and immunohistochemical evaluations tumors
were divided into molecular subgroups. Presence of variants was tested for potential association with the
occurrence of rare life-threatening AE and other clinical features.
Results: We have identified altogether six new potentially pathogenic variants in MSH2 (p.A733T and p.V606I),
RAD50 (p.R1093*), FANCM (p.L694*), ERCC2 (p.R695C) and EXO1 (p.V738L), in addition to two known NBN
variants. Five out of twelve patients with defects in either of MSH2, RAD50 and NBN genes suffered from rare
life-threatening AE, more frequently than in control group (p = 0.0005). When all detected variants were taken
into account, the majority of patients (8 out of 15) suffered from life-threatening toxicity during
chemotherapy.
Conclusion: Our results, based on the largest systematic study performed in a clinical setting, provide
preliminary evidence for a link between defects in DNA repair genes and treatment related toxicity in
children with medulloblastoma. The data suggest that patients with DNA repair gene variants could need
special vigilance during and after courses of chemotherapy.
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Background
Brain tumors represent the leading cause of childhood
cancer mortality. The most common malignant brain
tumor among them is medulloblastoma [1]. Although
multimodality treatment regimens have substantially im-
proved survival in this disease, up to 30-40% of patients
with medulloblastoma still die of the disease. Detrimental
effect of current treatment on long-term survivors is
also observed [2]. Our understanding of the molecular
background of pediatric brain tumors has expanded sig-
nificantly over the past few years. The vast amount of
genomic and molecular data generated recently has
proved that medulloblastoma is not a single entity but
is composed of at least four subtypes: Wingless (WNT),
Sonic Hedgehog (SHH), Group 3 and Group 4 (non-
WNT/SHH types), with distinct genetic and biological
profiles as well as different course of disease requiring
adequate therapeutic approaches [2–6]. Despite of im-
proved understanding of the molecular basis of medullo-
blastoma, many cases still lack an obvious genetic driver
[4, 7, 8]. The further research focused on additional poten-
tial mechanisms responsible for the development of this
tumor may lead to identification of new susceptibility
factors as well as new markers that predict response to
therapeutic agents and provide prognostic information. So
far, majority of driver mutations detected in medulloblas-
toma are of somatic character. Impact of germline genetic
variability that may affect clinicopathologic presenta-
tion of this tumor have not been in-depth investigated
yet [5, 7, 9–12].
In our study we focused on evaluation of germline
defects in genes that play a role in DNA repair pathway
because of the following reasons. Firstly, DNA-repair
deficiency is associated with cancer development and
the key role of germline alterations in promoting tumori-
genesis is highlighted by several cancer predisposition
syndromes e.g. Li-Fraumeni, Fanconi anemia or Turcot
syndrome, where occurrence of medulloblastoma has
been recorded. Secondly, it is well known that germline
defects may modulate the response to treatment since
DNA-repair mechanisms make cells prone to the effects
of DNA-damaging chemotherapy [13–15]. It is important
to notice that majority of evidence about the impact of
DNA-repair genes defects on toxicity in medulloblas-
toma comes from either description of single cases
[16, 17] or from mouse models and cell lines experi-
ments [13, 18] but not from systemic clinical based
investigation. Therefore, all these data indicate that
DNA repair genes are a promising targets possibly
linked both to development of tumor and response to
therapy in medulloblastoma.
Within essential components of DNA repair signaling
cascade the NBN gene particularly draws attention as
potentially susceptibility marker for medulloblastoma
[19, 20]. Germline defects in medulloblastoma patients
were observed also in other genes cooperated with NBN in
BRCA1-associated genome surveillance complex (BASC),
includingMSH6, PMS2 andMLH1 [21–24].
Biallelic defects in NBN gene result in Nijmegen Breakage
Syndrome (NBS; OMIM:251,260), while homozygous de-
fects in MSH6, PMS2 or MLH1 genes are molecular cause
of Constitutional Mismatch Repair Deficiency Syndrome
(CMRDS; OMIM:276,300), hereditary disorder associated
with increased risk of cancers including medulloblastoma
[25]. Among other genes responsible for CMRDS is also
MSH2 (ID:4436, MIM:609,309), one of the key factor of
DNA mismatch repair system which recognizes and repairs
mispaired or unpaired nucleotides resulted from DNA rep-
lication errors [25]. There is an evidence that germline
MSH2 defects may predispose to primary early-onset CNS
tumors, especially glioblastoma [26]. In addition, De
Rosa et al. suggest that in some families with Turcot
syndrome the coexistence of colorectal and childhood
brain tumors may result from a complete MMR deficiency
[27]. However, association between MSH2 defects and
medulloblastoma was not evaluated yet.
A very similar phenotype to NBS was seen in pa-
tients with Nijmegen Breakage Syndrome-like Disorder
(NBSLD – OMIM:613,078) caused by defects in the
RAD50 gene (ID:10,111, MIM:604,040). This gene en-
codes the protein involved in DNA double-strand break
repair, cell cycle checkpoint activation, telomere mainten-
ance and meiotic recombination suggesting that molecular
variants disrupting its function may lead to genome in-
stability and carcinogenesis [28]. Furthermore, inactivation
of proteins like RAD50 required for the homologous re-
combination machinery leads to defects in the nervous
system development indicating that components of this
system can play crucial role in development and pro-
gression of various neuro-oncological diseases [29]. The
frequency of the molecular variants in RAD50 gene was,
similarly to MSH2, not determined in medulloblastoma
patients up to now.
Therefore the first purpose of this study was to establish
the spectrum of germline defects in MSH2 and RAD50
genes, as well as frequency of two known NBN variants in
102 patients with medulloblastoma. In the next step we
have evaluated the hypothesis that DNA repair genes may
affect a response to therapy in medulloblastoma patients.
We have found that alterations in a range of DNA repair
genes are associated with occurrence of rare severe
adverse effects during chemotherapy in patients.
Methods
Patients and controls
A set of 102 medulloblastoma patients treated between
2004 and 2014 in the Neurosurgery and Oncology Depart-
ments of the Children’s Memorial Health Institute (CMHI)
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in Warsaw, Poland were investigated in this study. Based
on a combination of genomic and immunohistochemical
(IHC) analyses, patients were divided into molecular sub-
groups (see methods). Presence of metastases at diagnosis
was classified according to Chang et al. [30]. The clinical
characteristics of the study cohort is outlined in Table 1.
To estimate the population frequency of detected
MSH2 and RAD50 variants (independently of the data
deposited in the public databases) the population-
specific control group was assembled. DNA samples
from 300 healthy donors with negative cancer family
history and sex matched to the patients’ groups were
collected. To exclude potential bias between adult and
childhood population the control group consisted of
donors age matched to the study group.
Methods
A total DNA was extracted from peripheral blood and
tumors samples by use of the automatic magnetic
bead-based (MagnaPure, Roche) and phenol/chloro-
form methods, respectively [31].
To evaluate the sequence of MSH2 and RAD50 genes
in 102 patients with medulloblastoma targeted gene
panel sequencing was used. The NBN c.511A>G and
c.657_661del5 variant status was determined upon previ-
ously described conditions [19]. In three patients with
severe adverse events after the chemotherapy but with
no variants detected in MSH2, RAD50, and NBN genes
whole exome sequencing (WES) was carried out to
explore possible defects in other DNA repair genes.
Targeted gene panel sequencing
For generation of the targeted amplicon libraries the Ion
AmpliSeq™ Custom 3G-Panelv2 (275 bp; Life Technologies
Corporation; Carlsbad, CA, USA) consisting of 82 primer
pairs to target all exons of the MSH2 and RAD50 genes
(RefSeq:NM_000251.2 and RefSeq: NM_005732.3, respect-
ively) was used. Polymerase chain reaction (PCR) was per-
formed according to the manufacturer’s recommendations
with the Ion AmpliSeq™ Library Kit 2.0. Amplicon size
distribution and library concentration was determined
using Agilent DNA 1000 Kit (Agilent Technologies; Inc.,
Waldbronn, Germany). The final concentration of the
sample pool was measured by Qubit dsDNA BR Assay Kit
(Life Technologies Corporation; Carlsbad, CA, USA).
Emulsion PCR and sequencing was performed on an Ion
PGM Sequencer (Life Technologies Corporation; Carlsbad,
CA, USA) using 318 Chips and the Ion PGM 200
Sequencing Kit according to the manufacturer’s instruc-
tions. The sequence reads were mapped to the haploid hu-
man reference genome (hg19) with Novoalign (Novocraft
Technologies). SNVs and short insertions and deletions
(indels) were called using GATK version 2.8. [32] Variant
annotation was performed with Jannovar [33].
Whole exome sequencing
WES Library preparation was performed using Nextera
Rapid Capture Exome kit (Illumina). The samples were run
on ¼ of lane each on HiSeq 1500 using 2 × 75 bp paired-
end reads. After initial processing by the CASAVA, the
generated reads were aligned to the hg19 reference genome
with Burrows-Wheeler Alignment Tool and further proc-
essed by Genome Analysis Toolkit [32]. Base quality score
recalibration, indel realignment, duplicate removal and the
SNP/INDEL calling were done as described [34]. The
detected variants were annotated using Annovar5 [35].
Selection and validation of candidate variants
A way of prioritizing variants was based on three main
filtration steps, as follows:
1/. variants with the global minor allele frequency
(MAF) ≥ 0.01 (either in the 1000 Genomes Project,
ExAC Databases or in a matched control group)
were filtered out;
Table 1 The characteristics of 102 patients with medulloblastoma
Medulloblastoma patients Number of patients






















Abbreviations: LCA large cell/anaplastic, D/N desmoplastic/nodular, MBEN with
extensive nodularity, MBL medulloblastoma, subtype not known, NA not
available, PPNG Polish Pediatric Neurooncology Group, HR -PPNG High Risk
protocol, SR -PPNG Standard Risk protocol, <3 yrs. – PPNG protocol for children
younger than 3 years old
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2/.nonsynonymous SNPs, coding sequence insertion/
deletions (indels), and canonical splice-site variants
were selected;
3/. all variants occurring within DNA repair genes
detected by WES were prioritized;
4/. variants annotated as deleterious by three and more
prediction algorithms (PolyPhen-2, SIFT, Mutation
Taster and FATHMM), nonsense mutations and
deletions that introduce premature stop codons
were classified as likely pathogenic and selected into
further consideration. Functional consequences of
splice variants were predicted by Human Splicing
Finder, Splice Site Finder-like and MaxEntScan.
For all selected variants the amino acid position in func-
tional domains and posttranslational modifications were
verified using NCBI Protein [36] and Alamut-2.4-6 Soft-
ware (Interactive Biosoftware; Rouen, France). Their con-
tribution in carcinogenesis was verified in the Catalogue
of Somatic Mutations (COSMIC database) [37], Human
Gene Mutation Database (HGMD) [38], ClinVar database
and Online Mendelian Inheritance in Man (OMIM).
Correlation with the clinical features and the course of
disease was assessed for each candidate variant.
Variant validation
Next generation sequencing results were validated using
Sanger sequencing. Specific primers for PCR reactions
are available upon request. PCR products were se-
quenced in 3130 Genetic Analyzer and evaluated with
Sequencing Analysis Software v.5.4 (Applied Biosystems/
Life Technologies; Foster City, CA). The frequency of
validated variants were evaluated in the matched control
group in the same conditions. Additionally, prioritized
variants in MSH2 and RAD50 were cross-checked
with the parents’ sequence data to identify inherited
versus de novo changes. In four out of five carriers of
MSH2, RAD50, FANCM or EXO1 gene variants
tumour tissues were available and the presence of
identified changes (p.V606I, p.R1093*, p.L694* and
p.V738L) were verified.
Determination of molecular subgroups in medulloblastoma
patients
Tumors included in the study were divided into the
following molecular groups:
1/.WNT Group defined by the presence of at least two
features as recommended by the International
MedulloblastomaWorking Group [2]: CTNNB1
pathogenic variant, immunohistochemical positive
nuclear reaction against β-catenin (DB #610154,
1:800) and the presence of chromosome 6 monosomy.
The screening test for CTNNB1 variant analysis and
chromosome 6 monosomy were performed according
to methods described previously [39].
2/. SHH Group defined by the presence of
immunohistochemical positive reaction with
anti-GAB1 (Abcam #ab27439 and/or #59362,
1:100) and anti-YAP1 (Santa Cruz #sc-101,199,
1:50) antibodies [3].
3/.Non-WNT/SHH type (Group 3 or Group 4) included
the remaining tumors, tested negative for the above
features.
4/. For further discrimination of non-WNT/SHH tumours
(in order to identify Group 3 or Group 4) in patients
with detected DNA repair genes variants we applied
NanoString's nCounter System analysis (NanoString
Technologies, Seattle, USA). For identification of
clusters a series of 48 medulloblastoma tumours
were analized. Overall 30 non-WNT/SHH tumours
from this study were evaluated. Total RNA was
extracted from frozen or FFPE tumours using RNeasy
kits (Qiagen). RNA integrity was assessed using an
Agilent 2100 bioanalyzer. For four Groups
assignment NanoString CodeSet of 22 genes
has been applied as described by Northcott et al. [40]
Hybridization to the probes was performed in
NanoString Technologies, Seattle, USA. Data were
normalized and samples were clustered using nSolver
2.5 software.
Treatment complications assessment
Treatment related complications data were retrospectively
re-analyzed and assessed according to The Common
Toxicity Criteria (CTC), version 4.0. [41] For comparative
analyses only rare life-threatening adverse events of grade
4 (grade 5 was absent in our cohort) have been taken into
account since they are the most challenging complications
in clinical practice. The significance of assessed adverse
events frequency and other clinical features in groups of
patients with presence vs. absence of DNA repair genes
candidate variants were calculated using the Fisher
Exact test.
Results
MSH2 and RAD50 analysis
The analysis of MSH2 and RAD50 coding sequences in
102 medulloblastoma patients revealed 53 germline vari-
ants in total. Most of them (48/53; 90.6%) were single
nucleotide variants (SNV), while remaining (5/53; 9.4%)
were small indels (Additional file 1: Table S1). The num-
ber of identified variants ranged from 2 to 16, an average
of 7 variants per sample. After the filtration steps (three
heterozygous candidate variants including c.1816G>A
(p.V606I) and c.2197G>A (p.A733T) in MSH2, as well as
c.3277C>T (p.R1093*) in RAD50 were selected. All of
them were uncommon (1/102; 0.98% for each variant) in
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the patients group. None of them was observed in 1000
Genomes Project Database [42] as well as in the
matched control group of 300 samples. Allele frequency
of p.A733T MSH2 and p.R1093* RAD50 variants in ExAC
Database were 0.000005 and 0.000001, respectively. The
MSH2 p.V606I variant in ExAC Database was not re-
ported so far (Table 2).
Due to the lack or low frequency of candidate variants
in control groups, the estimation of cancer risk associ-
ated with the presence of identified variants was not
possible. DNA testing of probands’ parents confirmed
parental origin of all selected variants. The presence of
identified changes in tumor tissue had been proven for
MSH2 p.V606I and RAD50 p.R1093* variants. For
MSH2 p.A733T variant this analysis was not possible
because of the lack of tumor tissue.
Within the prioritized variants only p.R1093* in RAD50
gene (rs121912628) was reported as pathogenic in ClinVar
database (OMIM: 604,040.0001) and in the COSMIC list
of variants that have previously been associated with
cancer predisposition (COSM1060699) [37].
NBN c.511A>G and c.657_661del5 variants analysis
In 102 patients with medulloblastoma six carriers of NBN
germline likely pathogenic variants (c.511A>G or
c.657_661del5) were identified. Additional four NBN
carriers reported in our previous study [19] were included
in the analysis to increase a number of patients for
assessment of clinical relevance of detected NBN variants.
Whole exome sequencing analysis
In three patients with severe treatment complications but
no presence of MSH2, RAD50 and NBN candidate vari-
ants the exome sequence was analyzed. In all cases rare
candidate variants in genes essential for DNA repair path-
way were detected, including p.L694* in FANCM (ID
57697, MIM:609,644), p.R695C in ERCC2 (ID 2068,
MIM:126,340) and p.V738L in EXO1 (ID 9156,
MIM:606,063). None of identified variants was reported
in 1000 Genomes Database and in matched control group.
Two variants p.R695C in ERCC2 and p.V738L in EXO1
were found in ExAC Database with frequency
0.000000012 and 0.00000086, respectively. All detected
variant were present in heterozygous state (Table 2).
Characteristics of patients and tumors with molecular
variants in DNA repair genes
Distribution of clinical and biological features in patients
with molecular variants in essential for DNA repair
pathway genes is presented in Table 3.
There were no differences between groups of patients
with presence vs. absence of either of candidate variants
in MSH2, RAD50 and NBN genes in terms of age
(<3 years of age vs. ≥ 3 years, not significant, n.s), gender
(n.s), LCA pathology (n.s) and presence of metastases
(M2 M3 vs. M0 M1, n.s). Tumours belonged to WNT
Group (one tumour), Group 3 (one tumour) and Group
4 (8 tumours). Three tumours were not analyzed by
NanoString method due to the lack of RNA but they
belonged to non-WNT/SHH type (Group 3 or 4). In the
remaining three cases molecular type was not deter-
mined due to the lack of tumor material. It has been no-
ticed that none of the patients with SHH tumors had
MSH2, RAD50 or NBN variants (9 patients analyzed)
but these data did not reach statistical significance when
compared to other groups (n.s).
Four out of 12 patients with MSH2, RAD50 and NBN
molecular variants did not complete treatment protocol
because of reduction of the dose of drugs or delays above
100 days due to presence of various degrees of adverse
events. These included 4 out of 6 patients who died, there-
fore we refrained from examination of survival rates.
Among them one NBN c.657_661del5 carrier died due to
secondary leukemia 48 months after diagnosis.
To assess the potential impact of molecular defects on
the course of treatment we recorded that three out of 9
patients with presence of NBN variants and available
clinical data, suffered from rare grade 4 adverse events
during chemotherapy after the first course of treatment.
These included central nervous system toxicity, pneumo-
nia and colitis with gastrointestinal bleeding. For compari-
son, among 89 patients without molecular variants in
none of NBN, MSH2 and RAD50 genes only three patients
suffered from similar complications (enterocolitis grade 4,
gastrointestinal bleeding grade 4 and central nervous
system toxicity grade 4) despite an application of the same
PPNG protocol (Additional file 2: Figure S1 A and B) and
the difference was significant (p = 0.01). Moreover, two
out of three patients with identified variants in MSH2 or
RAD50 also displayed similar grade 4 complications,
namely central nervous system toxicity and pneumonia.
Therefore, 5 out of 12 patients with defects in either of
MSH2, RAD50 and NBN genes suffered from rare grade 4
adverse events during chemotherapy and these combined
results were even more significant when compared to the
control group (p = 0.0005) than for NBN gene alone.
Among patients with detected defects in MSH2, RAD50
and NBN genes High Risk arm of the PPNG protocol
(HR, Additional file 3: Table S2, Additional file 2:
Figure S1 A and B) which included Cisplatin and Ifosfa-
mide was not applied more frequently than in the series
of patients from control group without detected de-
fects in those genes (p = 0.13). When patients were
subdivided according to treatment arm, the results
pointing toward more frequent toxicity in patients
with identified variants were also statistically signifi-
cant (p = 0.01 for HR arm only, and p = 0.01 for
protocol for children <3 years old only).
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Because the above results indicate association between
defects in analyzed DNA repair genes and presence of
adverse effects during therapy we performed WES ana-
lyses in three patients who suffered from rare grade 4
adverse events but had no abnormalities inMSH2, RAD50
and NBN genes. In all three patients candidate variants
were detected in FANCM, ERCC2 and EXO1 genes which
are presented in Tables 2 and 3. In summary, taking into
account the WES results, among patients with detected
variants in DNA repair genes majority of them (8 out of
15; 53%) suffered from rare life-threatening grade 4
toxicity during the course of treatment.
Discussion
Assuming that the fundamental feature of cancer is
genomic instability, functional defects of proteins which
are responsible for maintenance of genome integrity by
correcting DNA replication errors, should be carcino-
genic. It is therefore not surprising that a number of
cancer susceptibility genes encode key factors of DNA
repair pathways. Recent comprehensive analysis of germline
mutations in pediatric cancers pointed to DNA repair genes
as the most commonly mutated genes, including TP53 and
BRCA2 [43]. It is also increasingly clear that defects in
DNA repair genes may determine patient’s response to
radio and chemotherapy [13, 16, 17]. In view of that we
evaluated the potential association between DNA repair de-
fects and treatment related toxicity as well as their potential
role as a susceptibility factor for medulloblastoma.
The sequence analysis of two well-known repair genes
MSH2 and RAD50 conducted in large cohort of 102
medulloblastoma patients revealed three new germline
variants MSH2 p.V606I and p.A733T as well as RAD50
p.R1093*. Both the localization and the character of
detected variants allow for prediction of their probably
pathogenic impact on the encoded proteins what was
supported by the results of the in silico analysis (Table 2).
The p.V606I and p.A733T substitutions are localized in
the crucial DNA mismatch repair protein V (MutSV - aa
619-854, pF00488) in highly (p.V606I- phyloP:4.40) and
moderate (p.A733T-phyloP:2.55) conserved amino acid
region. MutSV domain contains the dimerization inter-
face and nucleotide-binding site with C-terminal helix-U-
turn-helix motif that is critical for MutS function [44].
The RAD50 p.R1093* variant resulting in premature stop
codon has severe consequences on the protein translation
and predicts suppression of its protein. All identified
variants were uncommon in our patients (1/102; 0.98%).
This is consistent with the published data indicating that
molecular variants in MSH2 and RAD50 in CNS tumors
occurred very rarely (5/1637 – 0.31% and 4/1743 – 0.23%,
respectively [37]. In support of that, in published recently
study of germline mutations in pediatric cancers, includ-
ing medulloblastoma, MSH2 and RAD50 variants were
not reported [43]. Due to the lack or low frequency of
candidate variants in control groups the estimation of can-
cer risk associated with their presence was not possible
(Table 2). However, deleterious character of detected
germline variants, the role of the encoded proteins in
DNA repair system and their annotation with genetic syn-
dromes, including NBSLD and CMRDS associated with
medulloblastoma, make them the potential susceptibility
variants for this kind of tumor. The RAD50 p.R1093* vari-
ant was reported as one of two known molecular defects
(HGMD CMO92910) responsible for NBSLD. In medullo-
blastoma patients pathogenic variants in MLH1, MSH6
and PMS2 genes were detected previously [21–24, 43].
Alterations in these genes together with MSH2 defects
lead to CMRDS. Both MSH2 and RAD50 encode the
crucial components of the DNA repair system. MSH2
belongs to mismatch repair genes (MMR) while RAD50
together with MRE11 and NBN constitute the MRN
complex responsible for connecting DNA damage de-
tection to DNA repair and cell cycle checkpoint func-
tion [44, 45]. Biallelic deficiency in MMR genes had
been referred as a molecular cause of increased predis-
position to gastrointestinal and hematological malig-
nances, as well as early-onset CNS tumors (especially
glioblastoma; GBM) [22, 26]. Additionally, the germline
heterozygous variants in MMR gene were reported in pa-
tients with Turcot syndrome associated with medulloblas-
toma incidence. The molecular variants affecting genes of
the MRN complex might also play a role in pediatric
tumor development. The evidence that NBN heterozy-
gous variants predispose to childhood acute lympho-
blastic leukemia and medulloblastoma was already
published [19, 46–48]. All these facts reinforce potential
role of DNA repair genes, including MSH2 and RAD50 in
susceptibility to medulloblastoma but detailed mechanistic
studies are required to confirm this preliminary hypothesis.
Notwithstanding the role of DNA repair genes in patho-
genesis of medulloblastoma, it is profoundly important
from the clinical perspective that the presence of molecu-
lar defects in these genes may have an impact on the
course of treatment.
The MRN complex genes, including MRE11, NBN and
RAD50 are required for double-stand DNA break (DBS)
repair via one of the DNA repair system, homologous
recombination (HR). Defects in HR system lead to hyper-
sensitivity to agents that produce DSB and topoisomerase
inhibitors eg. etoposide [14, 15, 49]. MMR genes re-
move mispaired nucleotides by the cooperation in
mismatch repair system whose defects are associated
with hypersensitivity to DNA crosslinks and platinum-
based chemotherapeutic agents (eg. mitomycin C and
carboplatin) [14, 15, 49].
Medulloblastoma treatment protocol (Additional file 2:
Figure S1 A and B) includes the drugs mentioned above,
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specifically platinum-based chemotherapeutic agents (car-
boplatin, cisplatin), topoisomerase inhibitor etoposide
and, in addition, mitotic inhibitor vincristine. Therefore it
is very likely that our patients with molecular variants in
DNA repair genes may be more prone to complications in
recovering from chemotherapy induced DNA damage.
They include the patients with variants detected by WES
analysis in ERCC2, FANCM or EXO1 genes, an essen-
tial components of DNA repair systems [14]. All three
identified variants (p.R695C, p.L694* and p.V738L, re-
spectively) were localized in highly conserved nucleotide
position (phyloP: 0.89-0.99) in crucial for the encoded
protein domains (Table 2) and the character of detected
variants (nonsense and splice site) strengthens their
pathogenic role. Previous functional studies had also
linked these variants to increased sensitivity to thera-
peutic agents. Defects of ERCC2 protein were reported
as a cause of faults in the nucleotide excision repair
mechanism (NER) which is responsible for removal of
variety of helix-distorting DNA lesions, as well as a
hypersensitivity to platinum derivatives. The FANCM
gene is one of the elements of the Fanconi Anemia
(FANC) pathway responsible for DNA crosslinks repair,
possibly through coordination of three main DNA repair
systems: nonhomologus endjoing (NHEJ), homologus re-
combination (HR) and translesion DNA synthesis (TLS).
Loss of function of this system results in sensitivity to
DNA crosslinking agents and platinum derivatives
[14, 15, 49]. Finally, EXO1 gene encode a nuclease
which cooperates with MRN complex in DSB repair
via HR pathway as well as interacts with MMR genes
in repair of DNA mismatches [50, 51].
Although we acknowledge that functional studies are
necessary to explore the mechanism through which
DNA repair gene defects influence the treatment related
toxicity we have already found significant association be-
tween defects in NBN, MSH2, RAD50, FANCM, ERCC2
and EXO1 genes and clinical data. Indeed, more than
half of patients with variants in DNA repair genes suffered
from rare adverse grade 4 events after administration of
chemotherapy (Table 3). We acknowledge that validation
cohorts would be necessary for confirmation of our
results. Unfortunately, recently published NSG ‘discovery
sets’ of medulloblastoma ranged only from 39 to 92
samples and molecular defect in MSH2, RAD50 and NBN
gene were not identified [7, 9–12, 43]. Also, an informa-
tion related to the therapy and accompanied side effects
was not provided in these studies. However in two
pediatric medulloblastoma patients with mutations in
DNA repair genes (PALB2 and BRCA2) chemotherapy
inducted grade 4 side effects were reported [16, 17]. In
addition, effect of other drugs being introduced to medul-
loblastoma treatment protocols e.g. temozolomide (TZM)
may be dependent on the status of mismatch repair genes.
In melanoma one variant g.73170T>C in MSH2 gene
(rs2303428) was associated with response and side effects
and could be used as a molecular marker for TMZ treat-
ment response [52].
On the other hand it is difficult to compare toxic effects
caused by cancer treatment in adult patients harboring de-
fects in DNA repair genes with toxicity observed in still
developing and vulnerable tissues in children. Different
spectrum of tumors in children and therefore different
treatment protocols, including very high doses of drugs,
may influence dissimilar reaction in the latter population.
Conclusions
Our study was conducted in a single institution on the lar-
gest series of uniformly treated patients which provided
primary data indicating possible link between defects in
DNA repair genes and treatment related toxicity in
children. Given the complexity of the data in relation
to the rarity of medulloblastoma, our results needs to
be confirmed in independent cohorts. If proven, the
special vigilance during and after treatment of patients
with pathogenic variants in DNA repair genes should
be required. Also additional screening for the presence
of molecular variants in patients with manifestation of
severe adverse events is necessary to acquire more infor-
mation about their impact on the course of treatment.
Finally, the potential revision of the mode of treatment
should be considered for patients with germline defects in
DNA repair genes in the future.
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